Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,257.00-3.46%ETH$2,228.49-4.06%GOLD$3,964.60-1.66%OIL$103.97+1.93%
Smart Investors Daily
SID Premium
AO

NYSE · AORT

Artivion, Inc.

Healthcare · Medical - Devices

$23.44

Up+$0.52 (+2.27%)

Updated Oct 30, 2026, 1:10 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.84B
P/E ratio
187.45
Dividend yield
0.00%
52-week range
$19.16 – $48.25
Volume
418.2K
Avg. volume
384.16K

Price performance · AORT

AORT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

AORT closed at $23.44 after 21 trading sessions, up 6.89% for the selected period.

Last close
$23.44
Period change
+6.89%
Period low
$21.21
Period high
$23.97
Daily close
View OHLC price history
AORT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$23.80$23.80$23.05$23.44418.2K
Oct 28, 2026$22.59$23.38$22.59$22.92421.65K
Oct 27, 2026$22.98$23.15$22.61$22.94405.21K
Oct 26, 2026$23.12$23.63$22.91$22.98366.02K
Oct 23, 2026$23.86$24.20$22.91$23.30415.35K
Oct 22, 2026$23.03$24.24$23.03$23.97544.45K
Oct 21, 2026$22.76$23.31$22.69$22.90473.81K
Oct 20, 2026$22.95$23.69$22.81$23.09631.12K
Oct 19, 2026$21.68$22.51$21.52$22.28465.12K
Oct 16, 2026$21.83$22.37$21.635$21.78433.65K
Oct 15, 2026$22.02$22.49$21.53$21.87512.46K
Oct 14, 2026$21.32$21.745$21.08$21.53488.61K
Oct 13, 2026$21.83$22.40$21.30$21.36664.56K
Oct 12, 2026$21.21$21.91$21.09$21.79436.62K
Oct 9, 2026$21.15$21.60$20.21$21.26343.5K
Oct 8, 2026$21.45$21.45$20.89$21.21602.17K
Oct 7, 2026$21.80$22.40$21.59$21.61351.96K
Oct 6, 2026$22.83$23.31$21.65$21.84494.35K
Oct 5, 2026$22.21$23.04$22.16$22.61734.22K
Oct 2, 2026$22.07$22.72$21.60$22.31559.45K
Oct 1, 2026$22.87$23.11$21.86$21.93501.66K

Latest AORT news

The latest Smart Investors Daily articles mentioning AORT.

Stock researchCompany · Overview

AORT research

Overview

Company profile and research snapshot.

Company profile

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$47.50
Implied upside
—
Analysts
13
AORT recent ratings
DateFirmRatingTarget
Oct 20, 2026JefferiesBuy—
Aug 18, 2026Canaccord GenuityBuy—
Jul 20, 2026NeedhamBuy—
Jun 16, 2026Canaccord GenuityBuy—
May 8, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

Yahoo · Oct 20, 2026

Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’

Investing.com -- Artivion Inc (NYSE:AORT) shares gained 4.2% Tuesday after Jefferies initiated coverage on the cardiovascular medical device maker with a Buy rating and a $31 price target, framing the company as a compelling play on aortic surgery growth. The bullish call reflects optimism surrounding Artivion’s expanding product pipeline, which Wall Street expects to drive double-digit revenue expansion alongside expanding profit margins.

Yahoo · Oct 20, 2026

Artivion (AORT) Stock May Be 13% Undervalued On Cash Flow

Artivion has gone through a sharp reset in market expectations, with the share price down heavily over the past year yet still well ahead of where it was three years ago. That mix of long term gains and recent weakness puts the focus squarely on a single issue: whether the current price can be explained by the cash the business is expected to generate. Over the past 3 years the stock has gained 66.9%, which puts meaningful past returns on the line if the underlying cash flows do not support...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By